BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $982,386 | -16.7% | 14,432 | -0.1% | 0.06% | -7.5% |
| Q2 2023 | $1,178,737 | -29.2% | 14,440 | -35.7% | 0.07% | -29.5% |
| Q1 2023 | $1,665,862 | -11.5% | 22,454 | -1.1% | 0.10% | -12.0% |
| Q4 2022 | $1,881,376 | -2.0% | 22,700 | +235.9% | 0.11% | -2.7% |
| Q3 2022 | $1,919,000 | -19.0% | 6,758 | -1.1% | 0.11% | -3.5% |
| Q2 2022 | $2,370,000 | -21.4% | 6,836 | -1.9% | 0.12% | -4.2% |
| Q1 2022 | $3,017,000 | -17.4% | 6,966 | -1.3% | 0.12% | -7.7% |
| Q4 2021 | $3,651,000 | +6.8% | 7,057 | 0.0% | 0.13% | +3.2% |
| Q3 2021 | $3,420,000 | +4.7% | 7,057 | -2.8% | 0.13% | +8.6% |
| Q2 2021 | $3,268,000 | +1.8% | 7,257 | -13.6% | 0.12% | +10.5% |
| Q1 2021 | $3,209,000 | +7.9% | 8,402 | -10.3% | 0.10% | 0.0% |
| Q4 2020 | $2,975,000 | +9.9% | 9,368 | -14.3% | 0.10% | -3.7% |
| Q3 2020 | $2,707,000 | -11.7% | 10,926 | -5.9% | 0.11% | -17.4% |
| Q2 2020 | $3,065,000 | +36.7% | 11,605 | -1.9% | 0.13% | +5.6% |
| Q1 2020 | $2,242,000 | -15.2% | 11,826 | -1.9% | 0.12% | +40.4% |
| Q4 2019 | $2,645,000 | +11.4% | 12,049 | -0.7% | 0.09% | +4.7% |
| Q3 2019 | $2,374,000 | -14.0% | 12,134 | -8.4% | 0.08% | -7.6% |
| Q2 2019 | $2,761,000 | +3.8% | 13,244 | -1.1% | 0.09% | +7.0% |
| Q1 2019 | $2,660,000 | +25.4% | 13,396 | -8.6% | 0.09% | +11.7% |
| Q4 2018 | $2,121,000 | -30.0% | 14,656 | -1.2% | 0.08% | -28.7% |
| Q3 2018 | $3,028,000 | +17.2% | 14,835 | -15.0% | 0.11% | +14.9% |
| Q2 2018 | $2,583,000 | -10.9% | 17,461 | -9.0% | 0.09% | -16.8% |
| Q1 2018 | $2,898,000 | +16.1% | 19,186 | -0.4% | 0.11% | +15.3% |
| Q4 2017 | $2,497,000 | -4.1% | 19,271 | -10.6% | 0.10% | -14.8% |
| Q3 2017 | $2,604,000 | -5.9% | 21,544 | -8.5% | 0.12% | -4.2% |
| Q2 2017 | $2,766,000 | +6.0% | 23,544 | -8.3% | 0.12% | -5.5% |
| Q1 2017 | $2,610,000 | -3.0% | 25,679 | -1.8% | 0.13% | -6.6% |
| Q4 2016 | $2,690,000 | -6.8% | 26,162 | -0.7% | 0.14% | -9.9% |
| Q3 2016 | $2,886,000 | -4.9% | 26,352 | -2.0% | 0.15% | -13.7% |
| Q2 2016 | $3,034,000 | +16.3% | 26,900 | -2.5% | 0.18% | +15.9% |
| Q1 2016 | $2,608,000 | +8.5% | 27,587 | +3.3% | 0.15% | +10.2% |
| Q4 2015 | $2,403,000 | -29.0% | 26,704 | -27.0% | 0.14% | -37.4% |
| Q3 2015 | $3,384,000 | -8.3% | 36,603 | -2.3% | 0.22% | +2.8% |
| Q2 2015 | $3,691,000 | -6.7% | 37,481 | -5.0% | 0.21% | -7.0% |
| Q1 2015 | $3,958,000 | +35.5% | 39,464 | +24.8% | 0.23% | +29.4% |
| Q4 2014 | $2,921,000 | – | 31,611 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |